Fusion protein of extracellular domain (aa 71-273) of human LOX-1 with murine Fcgamma1 (LOX-1-muFc) produced in PEAK cells
IHC-Fr: human spleen cells.
ab81709 neutralizes the biological activity of LOX 1. It also inhibits Hsp70 binding to dendritic cells and Hsp70 induced antigen cross representation. In vivo, targeting LOX1 with a tumor antigen using anti LOX 1 antibody ab81709 induces anti tumor immunity.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Purification notesPurified and 0.2 µm filtered solution.
Primary antibody notesab81709 neutralizes the biological activity of LOX 1. It also inhibits Hsp70 binding to dendritic cells and Hsp70 induced antigen cross representation. In vivo, targeting LOX1 with a tumor antigen using anti LOX 1 antibody ab81709 induces anti tumor immunity.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. Antibody totally prevented Hsp70 binding to LOX-1-CHO but not mock-transfected CHO cells.
Use a concentration of 10 µg/ml. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
Use at an assay dependent concentration.
FunctionReceptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Tissue specificityExpressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver and brain, aortic intima, bone marrow, spinal cord and substantia nigra. Also expressed at the surface of dendritic cells. Widely expressed at intermediate and low level.
Involvement in diseaseNote=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility. Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.
Human spleen cells stained for LOX-1 immunolocalization (200x).
Immunohistochemical staining of frozen sections with antibody 23C11
References for Anti-LOX 1 antibody [23C11] (ab81709)
This product has been referenced in:
Li D et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med209:109-21 (2012).
Read more (PubMed: 22213806) »
Jeannin P et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity22:551-60 (2005).
ICC/IF, Flow Cyt
Read more (PubMed: 15894273) »